Affiliation: AstraZeneca R and D
- EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samplesGillian Ellison
AstraZeneca, Macclesfield, Alderley Park, UK
J Clin Pathol 66:79-89. 2013..We also evaluated data on the use of cytology samples in order to determine their suitability for EGFR mutation analysis...
- A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samplesGillian Ellison
AstraZeneca, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK
J Exp Clin Cancer Res 29:132. 2010..We have compared mutation analysis by DNA sequencing and Amplification Refractory Mutation System™ (ARMS™) for their ability to detect mutations in clinical biopsy specimens...
- Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244)Jonathan R Dry
Cancer Bioscience, DECS, and Clinical Biomarker Group, AstraZeneca R and D, Alderley Park, Macclesfield, United Kingdom
Cancer Res 70:2264-73. 2010..These signatures offer useful tools for the study of MEK biology and clinical application of MEK inhibitors, and the novel approaches taken may benefit other targeted therapies...